'Well un­der­way': FDA calls for faster con­fir­ma­to­ry tri­als for ac­cel­er­at­ed ap­provals

The FDA’s On­col­o­gy Cen­ter of Ex­cel­lence on Thurs­day out­lined what more the agency can do to speed up con­fir­ma­to­ry tri­als to en­sure drugs ap­proved un­der the ac­cel­er­at­ed path­way are clin­i­cal­ly ben­e­fi­cial.

Be­fore re­view­ing two Acrotech Bio­phar­ma ther­a­pies, FDA of­fi­cials took ques­tions from an ad­vi­so­ry com­mit­tee of can­cer ex­perts on the agency’s wider plans for re­form­ing the ac­cel­er­at­ed ap­proval process. Acrotech mar­kets two drugs: Folo­tyn (prala­trex­ate) and Beleo­daq (be­li­no­s­tat), both of which re­ceived ac­cel­er­at­ed ap­proval, are in­di­cat­ed for re­lapsed or re­frac­to­ry pe­riph­er­al T cell lym­phoma (PT­CL) and have lin­gered for years with­out com­plet­ing con­fir­ma­to­ry tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER